# Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease

> **NIH NIH R44** · VIVREON BIOSCIENCES, LLC · 2023 · $50,000

## Abstract

Vivreon Biosciences, LLC
4940 Carroll Canyon Rd. Suite 110
 San Diego, CA 92121
milton@vivreonbiosciences.com
Vivreon Biosciences – NIA SBIR #PA-20-272 – Administrative Supplements to Existing NIH Grants and
Cooperative Agreements; Notice of Special Interest (NOSI): Administrative Supplement for Providing Technical
and Business Assistance (TABA) Funding to SBIR/STTR Awardees (Admin Supp) Notice Number: NOT-OD-21-
062
Project Summary
Vivreon Biosciences is pleased to apply for NIA SBIR Supplement #PA-20-272 to develop intellectual property
protection for the preclinical candidate in our currently funded SBIR R44AG061995, “Preclinical Characterization
of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease”. Supplemental funding is urgently required
for intellectual property freedom-to-operate (FTO) analysis and patent filings.
The programmatic goal of R44AG061995 is to de-risk our novel Alzheimer’s therapeutic development candidate
to make this program an attractive investment opportunity for third-party investors and pharmaceutical partners.
To arrive at a highly promising patentable development candidate, our workflow involved rigorous lead
optimization and candidate selection studies. Vivreon medicinal chemists designed and synthesized new
chemical entities (NCEs) with calculated parameters suitable for a CNS drug, which were then tested in potency,
ADME, and DMPK assays. These efforts have yielded a candidate therapeutic that demonstrates drug-like
properties appropriate for further development. The Vivreon candidate therapeutic is orally bioavailable, highly
brain penetrant, and effective in mouse and human models of AD. TABA supplemental funding is urgently
required for technical and business services to support intellectual property protections.

## Key facts

- **NIH application ID:** 10837680
- **Project number:** 3R44AG061995-03S1
- **Recipient organization:** VIVREON BIOSCIENCES, LLC
- **Principal Investigator:** Milton L Greenberg
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $50,000
- **Award type:** 3
- **Project period:** 2022-09-15 → 2025-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10837680

## Citation

> US National Institutes of Health, RePORTER application 10837680, Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease (3R44AG061995-03S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10837680. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*